Compare Johnson & Johnson (JNJ) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Quanta Services Inc — how do they compare? Johnson & Johnson trades at $248.49 (market cap $598.96B), while Quanta Services Inc trades at $636.01 (market cap $94.92B). The key difference: Johnson & Johnson is far larger — about 6.3× Quanta Services Inc's market cap, and Johnson & Johnson pays the higher dividend (2.15%). Which is the better fit depends on your goals.
| JNJ | PWR | |
|---|---|---|
Market Cap | $598.96B | $94.92B |
Volume | 6,156,228 | — |
Sector | Health | Industrials |
52-Week High | $267.24 | $785.24 |
52-Week Low | $164.36 | $372.50 |
Enterprise Value | $631.90B | $100.88B |
Dividend Yield | 2.15% | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
PWR trades at $633.04, up 0.72% today, with strong analyst support (27 Buy, 0 Sell) and a consensus price target of $836.80. Recent quarters show consistent EPS beats, with Q1 2026 actual of $2.68 exceeding the $2.04 estimate. Revenue growth is robust, climbing from $17.1B in 2022 to $28.5B in 2025, though net margins remain modest at 3.67%. Technical indicators are mixed, with a bearish overall signal but bullish oscillators like RSI near oversold levels.
The outlook is positive due to infrastructure demand from AI and grid modernization, with a projected $2.4T addressable market by 2030. Risks include high valuation multiples (P/E 86.22) and aggressive capital spending impacting cash flow. Institutional sentiment is bullish, but execution risks and economic cycles could pressure near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
